ALTURiX has announced that it has acquired exclusive rights to three new products within the fields of gastrointestinal and respiratory medicine for commercialisation in the UK.
The new agreements align with the British pharmaceutical company’s aim to reliably and affordably supply important products to prescribers, patients, families and the NHS.
Gastrointestinal diseases affect the gastrointestinal tract from the mouth to the anus and respiratory diseases affect the airways in the lungs.
Respiratory diseases affect around one in five people and are currently the third-biggest cause of death in England.
Commenting on the new agreements, Lak Sahota, ALTURiX’s founder and director, responsible for business development at the company, said: “2024 is a transformational year for ALTURiX. We are very pleased to announce these three deals so early in the year. We are starting as we mean to continue.”
Across the past five years, ALTURiX has acquired several new products to add to its pipeline and has made subsequent effective market introductions.
Already, the company has a portfolio of well-known medicines that are widely prescribed via the NHS. Last year, the company celebrated 25 years of NHS supply through a range of cost-effective products to improve patient outcomes.
In October 2023, the company launched CEYESTO, a short-term melatonin oral solution to treat jet lag, in the UK, following the Medicines and Healthcare products Regulatory Agency’s decision to grant a broad range of licensed indications.
Furthermore, the company redefined the cost to the NHS of oral liquid melatonin products by pricing CEYESTO 80% less expensive than the drug tariff pricing for other liquid melatonin at the time, saving the NHS up to £23m every year in melatonin prescribing costs.
In addition, the solution has been approved for use in delayed sleep wake phase disorder in children aged six to 17 years and adults up to 25 years, and insomnia in children ages six to 17 years with attention deficit hyperactivity disorder.
